{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:43:23Z","timestamp":1792788203959,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"None (self-funded)","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s40360-015-0036-7","type":"journal-article","created":{"date-parts":[[2015,12,8]],"date-time":"2015-12-08T19:14:56Z","timestamp":1449602096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort"],"prefix":"10.1186","volume":"16","author":[{"given":"Evans L.","family":"Sagwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunurai","family":"Ruswa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farai","family":"Mavhunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Rennie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert G. M.","family":"Leufkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aukje K.","family":"Mantel-Teeuwisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,10]]},"reference":[{"key":"36_CR1","volume-title":"Guidelines for the programmatic management of drug-resistant tuberculosis","author":"World Health Organization (WHO)","year":"2008","unstructured":"World Health Organization (WHO). Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: Switzerland; 2008."},{"key":"36_CR2","volume-title":"National Guidelines for the Management of Tuberculosis","author":"Ministry of Health and Social Services (MoHSS)","year":"2012","unstructured":"Ministry of Health and Social Services (MoHSS). National Guidelines for the Management of Tuberculosis. 3rd ed. Windhoek: MoHSS; 2012.","edition":"3"},{"key":"36_CR3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(10)70139-0","volume":"10","author":"JA Caminero","year":"2010","unstructured":"Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10:621\u20139. www.thelancet.com\/infection Vol 10 September 2010.","journal-title":"Lancet Infect Dis"},{"key":"36_CR4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1128\/AAC.33.6.797","volume":"33","author":"RE Brummett","year":"1989","unstructured":"Brummett RE, Fox KE. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother. 1989;33:797\u2013800.","journal-title":"Antimicrob Agents Chemother"},{"key":"36_CR5","first-page":"601","volume":"15","author":"G Cianfrone","year":"2011","unstructured":"Cianfrone G, Pentangelo D, Altissimi G, Turchetta R. Pharmacological drugs inducing ototoxicity, vestibular symptoms and tinnitus: a reasoned and updated guide. Eur Rev Med Pharmacol Sci. 2011;15:601\u201336.","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"36_CR6","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1183\/09031936.00044812","volume":"40","author":"JA Seddon","year":"2012","unstructured":"Seddon JA, Godfrey-Faussett P, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J. 2012;40:1277\u201386.","journal-title":"Eur Respir J."},{"key":"36_CR7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/138161207779313731","volume":"13","author":"E Selimoglu","year":"2007","unstructured":"Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007;13:119\u201326.","journal-title":"Curr Pharm Des."},{"key":"36_CR8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2471\/BLT.13.128728","volume":"92","author":"BO Olusanya","year":"2014","unstructured":"Olusanya BO, Neumann J, Saunders JE. The global burden of disabling hearing impairment : a call to action. Bull World Health Organ. 2014;92:367\u201373.","journal-title":"Bull World Health Organ."},{"key":"36_CR9","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1128\/AAC.9.6.956","volume":"9","author":"RE Black","year":"1976","unstructured":"Black RE, Lau WK, Weinstein RJ, Young LS, Hewitt WL. Ototoxicity of Amikacin. Antimicrob Agents Chemother. 1976;9:956\u201361.","journal-title":"Antimicrob Agents Chemother."},{"key":"36_CR10","volume-title":"Report of an informal consultation on strategies for prevention of hearing impairment from ototoxic drugs","author":"World Health Organization (WHO)","year":"1994","unstructured":"World Health Organization (WHO). Report of an informal consultation on strategies for prevention of hearing impairment from ototoxic drugs. Geneva: Switzerland; 1994."},{"key":"36_CR11","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S1808-8694(15)31053-3","volume":"72","author":"LCB Jacob","year":"2006","unstructured":"Jacob LCB, Aguiar FP, Tomiasi AA, Tschoeke SN, De Bitencourt RF. Auditory monitoring in ototoxicity. Braz J Otorhinolaryngol. 2006;72:836\u201344.","journal-title":"Braz J Otorhinolaryngol."},{"key":"36_CR12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/014556131109000506","volume":"90","author":"R Singh Chauhan","year":"2011","unstructured":"Singh Chauhan R, Saxena RK, Varshey S. The role of ultrahigh-frequency audiometry in the early detection of systemic drug-induced hearing loss. Ear Nose Throat J. 2011;90:218\u201322.","journal-title":"Ear Nose Throat J."},{"key":"36_CR13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1682\/JRRD.2005.02.0039","volume":"42","author":"SA Fausti","year":"2005","unstructured":"Fausti SA, Wilmington DJ, Helt PV, Helt WJ, Konrad-Martin D. Hearing health and care: The need for improved hearing loss prevention and hearing conservation practices. J Rehabil Res Dev. 2005;42:45.","journal-title":"J Rehabil Res Dev."},{"key":"36_CR14","first-page":"440","volume":"99","author":"S Bardien","year":"2009","unstructured":"Bardien S, de Jong G, Schaaf HS, Harris T, Fagan J, Petersen L. Aminoglycoside-induced hearing loss : South Africans at risk. South African Med J. 2009;99:440\u20131.","journal-title":"South African Med J."},{"key":"36_CR15","first-page":"3","volume":"1","author":"G Perletti","year":"2008","unstructured":"Perletti G, Vral A, Patrosso MC, Marras E, Ceriani I, Willems P, et al. Prevention and modulation of aminoglycoside ototoxicity (Review). Mol Med Rep. 2008;1:3\u201313.","journal-title":"Mol Med Rep."},{"key":"36_CR16","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/jac\/dkr221","volume":"66","author":"A Sturdy","year":"2011","unstructured":"Sturdy A, Goodman A, Jos\u00e9 RJ, Loyse A, O\u2019Donoghue M, Kon OM, et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother. 2011;66:1815\u201320.","journal-title":"J Antimicrob Chemother."},{"key":"36_CR17","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2165\/00002018-200831100-00006","volume":"31","author":"BM Verdel","year":"2008","unstructured":"Verdel BM, van Puijenbroek EP, Souverein PC, Leufkens HGM, Egberts ACG. Drug-related nephrotoxic and ototoxic reactions : a link through a predictive mechanistic commonality. Drug Saf. 2008;31:877\u201384.","journal-title":"Drug Saf."},{"key":"36_CR18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1472-6815-7-5","volume":"7","author":"P Duggal","year":"2007","unstructured":"Duggal P, Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear Nose Throat Disord. 2007;7:5.","journal-title":"BMC Ear Nose Throat Disord."},{"key":"36_CR19","volume-title":"Namibia | Data [Internet]","author":"World Bank","year":"2015","unstructured":"World Bank. Namibia | Data [Internet]. 2015. [cited 2015 Jul 18]. Available from: http:\/\/data.worldbank.org\/country\/namibia . Accessed on 18 July 2015."},{"key":"36_CR20","volume-title":"UNAIDS Global Report, 2013","author":"UNAIDS. UNAIDS report on the global AIDS epidemic","year":"2013","unstructured":"UNAIDS. UNAIDS report on the global AIDS epidemic. UNAIDS Global Report, 2013. Geneva: UNAIDS; 2013."},{"key":"36_CR21","volume-title":"Global Tuberculosis Report, 2014","author":"World Health Organization (WHO)","year":"2014","unstructured":"World Health Organization (WHO). Global Tuberculosis Report, 2014. Geneva: World Health Organization; 2014."},{"key":"36_CR22","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2165\/11591360-000000000-00000","volume":"71","author":"KK Venkatesh","year":"2011","unstructured":"Venkatesh KK, Swaminathan S, Andrews JR, Mayer KH. Tuberculosis and HIV co-infection: screening and treatment strategies. Drugs. 2011;71:1133\u201352.","journal-title":"Drugs."},{"key":"36_CR23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1258\/0956462971919723","volume":"8","author":"S Monte","year":"1997","unstructured":"Monte S, Fenwick JD, Monteiro EF. Irreversible ototoxicity associated with zalcitabine. Int J STD AIDS. 1997;8:201\u20132.","journal-title":"Int J STD AIDS."},{"key":"36_CR24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1086\/324368","volume":"34","author":"D Rey","year":"2002","unstructured":"Rey D, L\u2019H\u00e9ritier A, Lang J. Severe Ototoxicity in a Health Care Worker Who Received Postexposure and Nevirapine after Occupational Exposure to HIV. Clin Infect Dis. 2002;34:418\u20139.","journal-title":"Clin Infect Dis."},{"key":"36_CR25","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1086\/320522","volume":"32","author":"J Simdon","year":"2001","unstructured":"Simdon J, Watters D, Bartlett S, Connick E. Ototoxicity associated with use of nucleoside analog reverse transcriptase inhibitors: a report of 3 possible cases and review of the literature. Clin Infect Dis. 2001;32:1623\u20137.","journal-title":"Clin Infect Dis."},{"key":"36_CR26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1590\/S0037-86822008000100012","volume":"41","author":"A Batista","year":"2008","unstructured":"Batista A, Vieira C, Greco DB. Otoneurological manifestations associated with antiretroviral therapy. Rev Soc Bras Med Trop. 2008;41:65\u20139.","journal-title":"Rev Soc Bras Med Trop."},{"key":"36_CR27","first-page":"574","volume":"4","author":"K Katijah","year":"2010","unstructured":"Katijah K. Is there a need for ototoxicity monitoring in patients with HIV\/AIDS? African J Pharm Pharmacol. 2010;4:574\u20139.","journal-title":"African J Pharm Pharmacol."},{"key":"36_CR28","volume-title":"National Guidelines for Antiretroviral Therapy","author":"Ministry of Health and Social Services (MoHSS)","year":"2010","unstructured":"Ministry of Health and Social Services (MoHSS). National Guidelines for Antiretroviral Therapy. 3rd ed. Windhoek: MoHSS; 2010.","edition":"3"},{"key":"36_CR29","unstructured":"ASHA. Degree of Hearing Loss [Internet]. ASHA; [cited 2015 Oct 15]. Available from: http:\/\/www.asha.org\/public\/hearing\/Degree-of-Hearing-Loss\/ . Accessed on 15 October 2015."},{"key":"36_CR30","first-page":"905","volume":"10","author":"M Reza","year":"2011","unstructured":"Reza M, Abtahi B, Gholami K. The Incidence of Amikacin Ototoxicity in Multidrug-Resistant Tuberculosis Patients. Iran J Pharm Res. 2011;10:905\u201311.","journal-title":"Iran J Pharm Res."},{"key":"36_CR31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/archotol.1964.00750040425010","volume":"80","author":"J Sataloff","year":"1964","unstructured":"Sataloff J, Wagner S, Menduke H. Kanamycin ototoxicity in healthy men. Arch Otolaryngol. 1964;80:413\u20137.","journal-title":"Arch Otolaryngol."},{"key":"36_CR32","first-page":"937861","volume":"2011","author":"ME Huth","year":"2011","unstructured":"Huth ME, Ricci AJ, Cheng AG. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol. 2011;2011:937861.","journal-title":"Int J Otolaryngol."},{"key":"36_CR33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1155\/S1565363304000056","volume":"10","author":"W Szczepanik","year":"2004","unstructured":"Szczepanik W, Kaczmarek P, Jezowska-Bojczuk M. Oxidative activity of copper(II) complexes with aminoglycoside antibiotics as implication to the toxicity of these drugs. Bioinorg Chem Appl. 2004;10:55\u201368.","journal-title":"Bioinorg Chem Appl."},{"key":"36_CR34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2302\/kjm.46.115","volume":"46","author":"SH Sha","year":"1997","unstructured":"Sha SH, Schacht J. Prevention of aminoglycoside-induced hearing loss. Keio J Med. 1997;46:115\u20139.","journal-title":"Keio J Med."},{"key":"36_CR35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1034\/j.1600-079x.2000.280104.x","volume":"28","author":"MA Lopez-Gonzalez","year":"2000","unstructured":"Lopez-Gonzalez MA, Guerrero JM, Torronteras R, Osuna C, Delgado F. Ototoxicity caused by aminoglycosides is ameliorated by melatonin without interfering with the antibiotic capacity of the drugs. J Pineal Res. 2000;28:26\u201333.","journal-title":"J Pineal Res."},{"key":"36_CR36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/01.moo.0000186799.45377.63","volume":"13","author":"AG Cheng","year":"2005","unstructured":"Cheng AG, Cunningham LL, Rubel EW. Mechanisms of hair cell death and protection. Curr Opin Otolaryngol Head Neck Surg. 2005;13:343\u20138.","journal-title":"Curr Opin Otolaryngol Head Neck Surg."},{"key":"36_CR37","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/toxsci\/kfr196","volume":"124","author":"T Karasawa","year":"2011","unstructured":"Karasawa T, Wang Q, David LL, Steyger PS. Calreticulin binds to gentamicin and reduces drug-induced ototoxicity. Toxicol Sci. 2011;124:378\u201387.","journal-title":"Toxicol Sci."},{"key":"36_CR38","doi-asserted-by":"crossref","unstructured":"Harris T, Bardien S, Schaaf HS, Petersen L, Jong G de, Fagan JJ. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. South African Med J. 2012. 363\u20136.","DOI":"10.7196\/SAMJ.4964"},{"key":"36_CR39","first-page":"1","volume-title":"Open Access Guide to Audiology and Hearing Aids for Otolaryngologists","author":"T Harris","year":"2013","unstructured":"Harris T, Heinze B. Open Access Guide to Audiology and Hearing Aids for Otolaryngologists. Cape Town: UCT; 2013. p. 1\u201317."},{"key":"36_CR40","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2334-6-28","volume":"6","author":"JT Schouten","year":"2006","unstructured":"Schouten JT, Lockhart DW, Rees TS, Collier AC, Marra CM. A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-na\u00efve people. BMC Infect Dis. 2006;6:28.","journal-title":"BMC Infect Dis."},{"key":"36_CR41","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2165\/00003088-197904030-00002","volume":"4","author":"J-C Pechere","year":"1979","unstructured":"Pechere J-C, Dugal R. Clinical Pharmacokinetics of Aminoglycoside Antibiotics. Clin Pharmacokinet. 1979;4:170\u201399.","journal-title":"Clin Pharmacokinet."},{"key":"36_CR42","first-page":"622","volume":"6","author":"P Jager De","year":"2002","unstructured":"De Jager P, Van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside. Int J Tuberc Lung Dis. 2002;6:622\u20137.","journal-title":"Int J Tuberc Lung Dis."},{"key":"36_CR43","doi-asserted-by":"crossref","first-page":"205427041453112","DOI":"10.1177\/2054270414531121","volume":"5","author":"N Nwobodo","year":"2014","unstructured":"Nwobodo N. Therapeutic drug monitoring in a developing nation: a clinical guide. JRSM Open. 2014;5:2054270414531121.","journal-title":"JRSM Open."},{"key":"36_CR44","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/thx.2009.131532","volume":"65","author":"A Prayle","year":"2010","unstructured":"Prayle A, Watson A, Fortnum H, Smyth A. Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax. 2010;65:654\u20138.","journal-title":"Thorax."}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-015-0036-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T03:49:31Z","timestamp":1567396171000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/2050-6511\/16\/36"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["36"],"URL":"https:\/\/doi.org\/10.1186\/s40360-015-0036-7","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"article-number":"36"}}